Personalized Prediabetes Prevention: Why a One-Size-Fits-All Approach May Not Work

New research suggests that current strategies for preventing type 2 diabetes in individuals with prediabetes may not be effective for everyone. A study presented at the 2026 American Heart Association Scientific Meeting highlights significant variations in individual risk levels, indicating a need for more tailored prevention plans.

Prediabetes on the Rise, Especially in Younger Adults

The increasing prevalence of both prediabetes and type 2 diabetes, particularly among adults under 40, is raising concerns. Type 2 diabetes can lead to serious long-term health complications, including heart disease, kidney disease, stroke, and nerve damage affecting the brain, eyes, and feet.

Significant Variation in Diabetes Progression Risk

Researchers followed 662 adults aged 18 to 40 diagnosed with prediabetes for an average of 7 years. They found a substantial range in the risk of developing type 2 diabetes within 5 years. The average risk was 7.5%, but this varied considerably among participants.

Risk Factors and GLP-1 Drug Criteria

Individuals meeting criteria for GLP-1 class drug treatment had a higher risk of progression to type 2 diabetes (10.9%). Those with fasting blood sugar levels between 110 to 125 mg/dL faced a 15.1% risk, whereas those with high fasting blood sugar levels and meeting GLP-1 drug criteria had the highest risk at 24.8%. This means that, within the same prediabetes stage, some individuals have a one-in-four chance of developing diabetes within five years.

The Need for Tailored Management Strategies

“Current type 2 diabetes prevention strategies are applied in virtually the same way to all patients,” explains Dr. Mary Rooney of Johns Hopkins Bloomberg School of Public Health, who led the study. “These results show that some high-risk groups require more aggressive and tailored management.”

Could GLP-1 Drugs Play a Preventative Role?

Currently, GLP-1 receptor agonists (GLP-1 RA) are approved for treating type 2 diabetes and obesity, and for weight loss when combined with lifestyle changes. Prescription criteria include a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity like high blood pressure or hyperlipidemia. They are not currently approved for preventing diabetes in prediabetic patients.

Researchers suggest GLP-1 RA drugs may facilitate prevent type 2 diabetes progression in overweight or obese prediabetic patients with related conditions. However, the cost-effectiveness of this approach in high-risk groups remains to be determined.

Lifestyle Interventions Remain Crucial

The American Heart Association emphasizes the importance of weight loss, a balanced diet, and regular physical activity in reducing diabetes risk. These lifestyle changes also lower the risk of high blood pressure, heart attack, and stroke.

Study Limitations

This study had some limitations. It did not include data on glycated hemoglobin (HbA1c), which reflects average blood sugar levels over 2-3 months, relying solely on fasting blood sugar levels. The data was collected before GLP-1 drugs were widely approved for weight loss, potentially differing from current clinical practice.

Frequently Asked Questions

• Does everyone with prediabetes progress to diabetes? No. The average risk of progression is about 7.5%, but varies up to 24.8% depending on individual factors. Not everyone will develop diabetes.
• Who is at higher risk of developing diabetes? Risk is higher with fasting blood sugar levels between 110-125 mg/dL, or the presence of metabolic diseases like obesity, high blood pressure, or hyperlipidemia, especially when these conditions occur together.
• Can diabetes be prevented with GLP-1 drugs? Currently, GLP-1 drugs are approved only for diabetes treatment or weight loss, not for prevention. While they may be helpful in some high-risk groups, their cost-effectiveness and preventative effects haven’t been fully proven.